Intuitive Surgical develops, produces, and commercializes the da Vinci surgical system and the Ion endoluminal system, along with instruments, accessories, training, and digital solutions that drive a large installed-base and recurring-revenue model.
ISRG
· Healthcare · Medical - Instruments & Supplies
· Market cap $141.14B
QuantHub Original Research · Updated 2026-09-25
·
High QualityA-tier business, B-tier valuation with 22.4% upside to $488.97 fair value.CheapIn Buy Zone
ISRG is 21% below fair value and in its buy zone. Consider adding to your position.
QuantHub Research: Investment Thesis
Scaling Phase
Intuitive Surgical develops, produces, and commercializes the da Vinci surgical system and the Ion endoluminal system, along with instruments, accessories, training, and digital solutions that drive a large installed-base and recurring-revenue model. Business quality is high: TTM gross margin of 66.7%, operating margin of 31.3%, net margin of 28.4%, ROE of 17.8%, and revenue growth of 18.5% with earnings growth of 24.3% in the most recent quarter. The stock trades at $399.52, or 12.79x sales, 45.12x trailing earnings, 43.95x free cash flow, and 30.71x EV/EBITDA, which screens as cheap relative to its own five-year history but still reflects a premium absolute multiple. Blended fair value of $488.97 implies 22.4% upside, and analyst consensus is Strong Buy with the same average target, so the shares look undervalued versus blended fair value even though they are not statistically cheap on absolute multiples. The central debate is whether procedure growth and system placements can sustain the premium multiple against China reimbursement reform, Medtronic's Hugo entry, tariff-driven gross-margin pressure, and product-family concentration.
The stock has fallen sharply in 2026, with one source noting a 29% year-to-date decline, which has compressed the multiple to 12.79x sales, 45.12x trailing earnings, 43.95x free cash flow, and 30.71x EV/EBITDA. That is still a premium absolute valuation, but the quantitative regime classifies it as cheap versus its own five-year history, and the blended fair value of $488.97 implies 22.4% upside. Sentiment appears to have overshot to the downside on China reimbursement reform, Medtronic's Hugo clearances, and tariff-related margin pressure, while the analyst consensus remains Strong Buy with a $488.97 average target. The gap between the depressed share price and the unchanged consensus target is the core mispricing: the market is pricing regulatory and competitive risk as if it were already in the numbers, while the most recent quarter still showed 18.5% revenue growth and 24.3% earnings growth.
12–18 Month Outlook
Over the next 18 months, Intuitive Surgical should remain a high-margin, double-digit grower, but the pace will depend on whether China's provincial implementation of the NHSA robotic-surgery pricing framework pressures procedure volumes and whether Medtronic's Hugo gains traction in U.S. general surgery, hernia, and gynecology. The most recent quarter's 18.5% revenue growth and 24.3% earnings growth, combined with TTM operating margins of 31.3%, suggest the base business is intact, while full-year 2026 non-GAAP gross-margin guidance of 68.0% to 69.0% embeds roughly 1.0% of tariff headwind. At $399.52, the shares trade at 12.79x sales and 43.95x trailing earnings, which is cheap versus the company's own five-year history but still a premium absolute multiple, so the 22.4% upside to the $488.97 blended fair value is plausible only if procedure growth holds near recent levels and margin pressure stays contained. If China or competitive pressures bite harder than expected, the multiple has room to compress further, as the 29% year-to-date decline already demonstrated.
Bull vs Bear
Bull Case
The most recent quarter showed revenue growth of 18.5% and earnings growth of 24.3%, demonstrating that the core procedure and instrument flywheel is still compounding at a healthy rate.
TTM gross margin of 66.7%, operating margin of 31.3%, and net margin of 28.4% reflect a high-margin recurring-revenue model built on instruments, accessories, and services tied to a large installed base.
The stock trades at 12.79x sales and 43.95x free cash flow after a 29% year-to-date decline, and the quantitative valuation regime classifies it as cheap relative to its five-year history.
Blended fair value of $488.97 implies 22.4% upside, and analyst consensus is Strong Buy with an average target of $488.97, suggesting the selloff has outrun fundamental deterioration.
The Ion endoluminal system and the expanding digital and robotics ecosystem broaden the addressable market beyond da Vinci surgery, supporting the next leg of procedure and placement growth.
Bear Case
China's NHSA unified national robotic-surgery pricing framework, issued in the second quarter of 2026, requires provincial implementation that could reduce procedure volumes or pressure instruments and accessories revenue, even though the effect was not material as of the July 21, 2026 filing.
Medtronic's Hugo system received U.S. urology clearance in December 2025 and Medtronic submitted U.S. filings in June 2026 to add general-surgery, hernia, and gynecology indications, directly threatening Intuitive's core categories.
Full-year 2026 non-GAAP gross-margin guidance of 68.0% to 69.0% includes an estimated tariff effect of approximately 1.0% of revenue, and further trade-cost pressure could reduce profitability.
The company remains heavily dependent on da Vinci and Ion, so any disruption in product availability, adoption, regulatory status, or clinical perception could materially affect system sales and high-margin recurring revenue.
At 45.12x trailing earnings, 43.95x free cash flow, and 30.71x EV/EBITDA, the multiple can compress sharply if procedure growth, placements, or margins disappoint, and the stock has already demonstrated that sensitivity with a 29% year-to-date decline.
Leadership & Competitive Position
David J. Rosa
Beats guidance75% of qtrs
Capital allocationGood
David J. Rosa is identified as the chief executive officer of Intuitive Surgical in the current company profile. The company was founded in 1995 and went public in 2000, and it has scaled to 17,021 full-time employees while maintaining TTM gross margins of 66.7% and operating margins of 31.3%. The cited research does not provide sufficient detail on his tenure, insider ownership, or capital-allocation history to make a stronger assessment.
Competitive Moat
stable
switching costsintangible assetsbrand
Intuitive Surgical is described as a leading medical technology firm and the maker of the da Vinci Surgical System, the flagship platform for minimally invasive surgery, with the Ion endoluminal system extending its reach into diagnostic lung procedures. The cited research does not provide a specific numerical market-share figure, but it characterizes the company as a leader with rapid procedure growth, an expanding robotics ecosystem, and recurring revenues.
Competitors: Medtronic (MDT), Stryker (SYK)
Disruption: Medium, because Medtronic's Hugo system received U.S. urology clearance in December 2025 and Medtronic filed in June 2026 to add general-surgery, hernia, and gynecology indications, which could erode Intuitive's procedure share in core categories over time.
QuantHub Research
Valuation
Multiple
Current
Median 3yr
Median 5yr
Min 5yr
Max 5yr
P/E
45.12x
70.8x
71.33x
65.89x
79.81x
P/S
12.79x
20.08x
20.08x
15.17x
22.41x
P/FCF
43.95x
142.2x
98.48x
73.71x
158.06x
P/S 12.79x vs 5yr range 15.17-22.41x (P25=15.17x, median=20.08x, P75=22.2x)
Price Outlook (5-Year)
Bear
$391
-0.7%/yr
Base
$489
3.8%/yr
fair value
Bull
$587
7.7%/yr
Bear/Base/Bull anchored to QuantHub fair value estimate. Base = headline fair value; Bear −20%; Bull +20%.
China's NHSA issued a unified national robotic-surgery pricing framework in the second quarter of 2026, and required provincial implementation could reduce procedure volumes or pressure instruments and accessories revenue, even though the effect was not material as of the July 21, 2026 filing.
Competitive pressure
medium
Medtronic's Hugo system received U.S. urology clearance in December 2025, and Medtronic submitted U.S. filings in June 2026 to add general-surgery, hernia, and gynecology indications, raising competitive risk in important robotic-surgery categories.
Valuation compression
medium
The stock trades at 45.12x trailing earnings, 43.95x free cash flow, 30.71x EV/EBITDA, and 12.79x sales, and these multiples can decline sharply if procedure growth, placements, or margins disappoint.
Tariffs and margin pressure
medium
Full-year 2026 non-GAAP gross-margin guidance of 68.0% to 69.0% includes an estimated tariff effect of approximately 1.0% of revenue, and further trade-cost pressure could reduce profitability.
Litigation and product safety
medium
Intuitive continues to face claims involving its products, and any adverse litigation outcome, safety event, or product-performance issue could result in financial losses and damage surgeon, hospital, and patient confidence.
Product-family concentration
medium
The company remains heavily dependent on da Vinci and Ion systems, and a disruption in product availability, adoption, regulatory status, or clinical perception could materially affect system sales and high-margin recurring revenue.
Growth Engines
da Vinci procedure growthscaling
Procedure growth remains the primary driver, with the most recent quarter showing 18.5% revenue growth and 24.3% earnings growth, supported by an expanding installed base and recurring instrument and accessory revenue.
Ion endoluminal systemscaling
The Ion system addresses minimally invasive lung biopsies and diagnostic interventions, extending the company beyond surgery into a large adjacent diagnostic market.
Digital and connected solutionsearly
The company integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights, and it is being grouped with AI-powered medical stocks as a beneficiary of precision-medicine adoption.
International expansionscaling
The company sells across international markets, and while China reimbursement reform creates near-term uncertainty, international procedure adoption remains a long-duration growth vector.
Intuitive Surgical stock has plunged 29% this year, with analysts still seeing upside
The sharp year-to-date decline has compressed the multiple to 12.79x sales and 43.95x trailing earnings, creating a gap versus the $488.97 consensus target and the 22.4% implied upside.
2026-09-24
Intuitive Surgical named among AI-powered medical stocks to buy for Q4
The company is being grouped with AI-enabled medical-device peers, highlighting its digital and connected-solutions positioning as a sentiment support.
2026-09-23
Intuitive Surgical compared favorably with Stryker on procedure growth and recurring revenue
The comparison emphasizes rapid procedure growth, an expanding robotics ecosystem, and recurring revenues as the core of the growth path amid MedTech shifts.
This is AI-powered fundamental analysis built from scratch — not aggregated analyst ratings. Get this research for your entire portfolio plus daily briefings, research signals, and options income.
QuantHub research is focused on quality businesses with durable competitive advantages — companies we'd want to own for 3–5 years or more. We are not short-term traders. Every analysis is built around a single question: is this a great business available at a reasonable price for a long-term investor?
We start where most analysts finish: the fundamentals. For every company, our AI ingests years of financial statements — revenue, margins, free cash flow, and how the business has been valued by the market across multiple cycles. But numbers alone don't tell you whether a business is worth owning.
The harder work is qualitative. We assess the competitive moat: is it widening or eroding? We read the leadership track record — how capital has been allocated, whether management has earned trust through consistent execution. We look at what the market is afraid of, and whether that fear is priced in fairly or irrationally.
Valuation is always relative. A stock is cheap or expensive compared to its own history. We build scenario matrices anchored to 5-year historical multiples, then ask: what has to go right for the upside case, and what's the floor if it doesn't?
Finally, we write an 18-month forward outlook — not a price target, but a mental model of where this business will be and what the narrative will look like. Every note is dated and versioned. When material facts change, we update the thesis.
Frequently Asked Questions
Is ISRG undervalued?
Yes, ISRG appears undervalued at the current price of $405.18, trading below our fair value estimate of $488.97 (+21% upside). QuantHub considers this a buy zone.
What is ISRG's fair value?
QuantHub Research estimates ISRG's fair value at $488.97 based on our proprietary valuation model incorporating historical P/S, P/E, and P/FCF multiples over a 5-year range.
What are the key risks for ISRG?
China reimbursement and pricing regulation: China's NHSA issued a unified national robotic-surgery pricing framework in the second quarter of 2026, and required provincial implementation could reduce procedure volumes or pressure instruments and accessories revenue, even though the effect was not material as of the July 21, 2026 filing. Competitive pressure: Medtronic's Hugo system received U.S. urology clearance in December 2025, and Medtronic submitted U.S. filings in June 2026 to add general-surgery, hernia, and gynecology indications, raising competitive risk in important robotic-surgery categories. Valuation compression: The stock trades at 45.12x trailing earnings, 43.95x free cash flow, 30.71x EV/EBITDA, and 12.79x sales, and these multiples can decline sharply if procedure growth, placements, or margins disappoint.
What is the bull case for ISRG?
The most recent quarter showed revenue growth of 18.5% and earnings growth of 24.3%, demonstrating that the core procedure and instrument flywheel is still compounding at a healthy rate. TTM gross margin of 66.7%, operating margin of 31.3%, and net margin of 28.4% reflect a high-margin recurring-revenue model built on instruments, accessories, and services tied to a large installed base. The stock trades at 12.79x sales and 43.95x free cash flow after a 29% year-to-date decline, and the quantita
How confident is QuantHub in ISRG?
QuantHub has moderate conviction in ISRG. Research last updated 2026-09-25.